Literature DB >> 33337557

Emerging trends in chromatin remodeler plasticity in mesenchymal stromal cell function.

Sayan Chakraborty1,2, Sayantani Sinha1,2, Amitava Sengupta1,2.   

Abstract

Emerging evidences highlight importance of epigenetic regulation and their integration with transcriptional and cell signaling machinery in determining tissue resident adult pluripotent mesenchymal stem/stromal cell (MSC) activity, lineage commitment, and multicellular development. Histone modifying enzymes and large multi-subunit chromatin remodeling complexes and their cell type-specific plasticity remain the central defining features of gene regulation and establishment of tissue identity. Modulation of transcription factor expression gradient ex vivo and concomitant flexibility of higher order chromatin architecture in response to signaling cues are exciting approaches to regulate MSC activity and tissue rejuvenation. Being an important constituent of the adult bone marrow microenvironment/niche, pathophysiological perturbation in MSC homeostasis also causes impaired hematopoietic stem/progenitor cell function in a non-cell autonomous mechanism. In addition, pluripotent MSCs can function as immune regulatory cells, and they reside at the crossroad of innate and adaptive immune response pathways. Research in the past few years suggest that MSCs/stromal fibroblasts significantly contribute to the establishment of immunosuppressive microenvironment in shaping antitumor immunity. Therefore, it is important to understand mesenchymal stromal epigenome and transcriptional regulation to leverage its applications in regenerative medicine, epigenetic memory-guided trained immunity, immune-metabolic rewiring, and precision immune reprogramming. In this review, we highlight the latest developments and prospects in chromatin biology in determining MSC function in the context of lineage commitment and immunomodulation.
© 2020 Federation of American Societies for Experimental Biology.

Keywords:  cell differentiation; chromatin remodeling; epigenetics; gene regulation; hematopoiesis; inflammation; innate immunity; mesenchymal stem cells (MSCs); tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33337557     DOI: 10.1096/fj.202002232R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  2 in total

Review 1.  Epigenetic therapy targeting bone marrow mesenchymal stem cells for age-related bone diseases.

Authors:  Yi Zhao; Jiawei He; Tao Qiu; Haoyu Zhang; Li Liao; Xiaoxia Su
Journal:  Stem Cell Res Ther       Date:  2022-05-16       Impact factor: 8.079

2.  ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment.

Authors:  Martina Chiu; Giuseppe Taurino; Erica Dander; Donatella Bardelli; Alessandra Fallati; Roberta Andreoli; Massimiliano G Bianchi; Cecilia Carubbi; Giulia Pozzi; Laura Galuppo; Prisco Mirandola; Carmelo Rizzari; Saverio Tardito; Andrea Biondi; Giovanna D'Amico; Ovidio Bussolati
Journal:  Blood Adv       Date:  2021-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.